Breast Cancer — Letrozole in Breast Cancer Who Have Received 5 Years of Aromatase Inhibitor Therapy
Citation(s)
A Double Blind Randomization to Letrozole or Placebo for Women Previously Diagnosed With Primary Breast Cancer Completing Five Years of Adjuvant Aromatase Inhibitor Either as Initial Therapy or After Tamoxifen (Including Those in The MA.17 Study)